Letter

Lipid lowering drugs in diabetes: Abstract was misleading

BMJ 2006; 332 doi: 10.1136/bmj.332.7552.1272 (Published 25 May 2006)
Cite this as: BMJ 2006;332:1272.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Mieke L van Driel, editor, Minerva Belgian Journal for Evidence Based Medicine (mieke.vandriel@ugent.be),
  2. Pierre Chevalier, editor, Minerva Belgian Journal for Evidence Based Medicine
  1. Department of General Practice and Primary Health Care, Ghent University, De Pintelaan 185 UZ 1K3, B-9000 Ghent, Belgium
  2. Centre Universitaire de Médecien Générale, Université Catholique de Louvain, Belgium

    EDITOR—The meta-analysis by Costa et al tackles clinically relevant issues by evaluating the effect of lipid lowering treatment in primary compared with secondary prevention and diabetic patients compared with non-diabetic patients.1 The authors' conclusions as reported in the abstract may have important implications for guide-line recommendations and marketing of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular